{"id":"til-il2","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Tumor-infiltrating lymphocytes (TILs) are harvested from a patient's own tumor, expanded ex vivo, and reinfused along with interleukin-2 (IL-2) to enhance T cell proliferation and activation. IL-2 acts as a growth factor to support the expansion and persistence of these tumor-reactive T cells, enabling them to recognize and eliminate cancer cells.","oneSentence":"TIL + IL-2 combines tumor-infiltrating lymphocytes with interleukin-2 to expand and activate patient-derived T cells for adoptive cell therapy against cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:38.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT02621021","phase":"PHASE2","title":"A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-04","conditions":"Melanoma","enrollment":170},{"nctId":"NCT02360579","phase":"PHASE2","title":"Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2015-09-24","conditions":"Metastatic Melanoma","enrollment":220},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT06961786","phase":"PHASE1","title":"TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2025-06-25","conditions":"Metastatic Melanoma","enrollment":9},{"nctId":"NCT07444437","phase":"PHASE2","title":"LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","startDate":"2026-02-26","conditions":"Non-Small Cell Lung Cancer","enrollment":45},{"nctId":"NCT07310784","phase":"PHASE2","title":"A Phase II Trial of LM103 in Advanced Melanoma","status":"RECRUITING","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","startDate":"2025-12-16","conditions":"Advanced Melanoma","enrollment":92},{"nctId":"NCT07443020","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors","status":"NOT_YET_RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT04426669","phase":"PHASE1, PHASE2","title":"A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering","status":"COMPLETED","sponsor":"Intima Bioscience, Inc.","startDate":"2020-05-15","conditions":"Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract","enrollment":23},{"nctId":"NCT05566223","phase":"PHASE1, PHASE2","title":"CISH Inactivated TILs in the Treatment of NSCLC","status":"WITHDRAWN","sponsor":"Intima Bioscience, Inc.","startDate":"2023-02","conditions":"Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04052334","phase":"PHASE1","title":"Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-09-27","conditions":"Sarcoma","enrollment":9},{"nctId":"NCT01659151","phase":"PHASE2","title":"Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-08-03","conditions":"Metastatic Melanoma","enrollment":17},{"nctId":"NCT06237881","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-31","conditions":"Advanced Solid Tumor, Melanoma, Lung Neoplasms","enrollment":15},{"nctId":"NCT07288073","phase":"PHASE2","title":"TIL Therapy in cSCC and MCC","status":"RECRUITING","sponsor":"Karam Khaddour, MD, MS","startDate":"2026-02-10","conditions":"Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma","enrollment":14},{"nctId":"NCT07406724","phase":"PHASE2","title":"HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","startDate":"2026-02-26","conditions":"Melanoma (Excluding Uveal Melanoma)","enrollment":90},{"nctId":"NCT06598371","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-21","conditions":"Select Advanced Solid Tumors","enrollment":141},{"nctId":"NCT05607095","phase":"PHASE1","title":"A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-11-01","conditions":"Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma","enrollment":30},{"nctId":"NCT06334783","phase":"PHASE1","title":"TIL for Patients With Advanced Solid Tumor","status":"TERMINATED","sponsor":"Hervor Therapeutics","startDate":"2023-05-30","conditions":"Advanced Solid Tumor","enrollment":5},{"nctId":"NCT05868915","phase":"PHASE1","title":"HV-101 for Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hervor Therapeutics","startDate":"2023-08-04","conditions":"Advanced Solid Tumors","enrollment":1},{"nctId":"NCT07349160","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-10","conditions":"Advanced Solid Tumors","enrollment":36},{"nctId":"NCT07192900","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease","status":"RECRUITING","sponsor":"David Bartlett, MD","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT07288203","phase":"PHASE2","title":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2025-11-28","conditions":"Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma","enrollment":100},{"nctId":"NCT05902520","phase":"PHASE1","title":"Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgonOx, Inc.","startDate":"2023-06-19","conditions":"HNSCC, Melanoma, Gynecologic Cancer","enrollment":18},{"nctId":"NCT06236425","phase":"PHASE1","title":"TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-14","conditions":"Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT05628883","phase":"PHASE1","title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-11-22","conditions":"Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma","enrollment":17},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT06626256","phase":"PHASE1","title":"STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2025-12-05","conditions":"Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Malignant Solid Neoplasm","enrollment":""},{"nctId":"NCT01319565","phase":"PHASE2","title":"Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03-24","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":102},{"nctId":"NCT01701674","phase":"NA","title":"Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-10-09","conditions":"Metastatic Melanoma","enrollment":13},{"nctId":"NCT01005745","phase":"NA","title":"Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-10-20","conditions":"Metastatic Melanoma","enrollment":19},{"nctId":"NCT07255664","phase":"PHASE1, PHASE2","title":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","status":"RECRUITING","sponsor":"Curacell Holding AB","startDate":"2025-11-13","conditions":"Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced","enrollment":12},{"nctId":"NCT05681780","phase":"PHASE1","title":"Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-03-10","conditions":"Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer","enrollment":13},{"nctId":"NCT05768347","phase":"PHASE1","title":"Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-10","conditions":"Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma","enrollment":9},{"nctId":"NCT06961357","phase":"PHASE1, PHASE2","title":"Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-01-01","conditions":"Melanoma","enrollment":36},{"nctId":"NCT06940739","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2025-03-11","conditions":"Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma","enrollment":42},{"nctId":"NCT05035407","phase":"PHASE1","title":"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-08","conditions":"Kita-kyushu Lung Cancer Antigen 1, Human","enrollment":36},{"nctId":"NCT03449108","phase":"PHASE2","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-04-27","conditions":"Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone","enrollment":30},{"nctId":"NCT06455917","phase":"PHASE2","title":"TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-01-22","conditions":"Non-Small Cell Lung Cancer, Lung Cancer (NSCLC)","enrollment":30},{"nctId":"NCT04614103","phase":"PHASE2","title":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2021-05-07","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":170},{"nctId":"NCT06481592","phase":"PHASE2","title":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2024-10-29","conditions":"Endometrial Cancer","enrollment":60},{"nctId":"NCT01955460","phase":"PHASE1","title":"Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-15","conditions":"Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7","enrollment":34},{"nctId":"NCT04812470","phase":"PHASE1","title":"Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2023-02-06","conditions":"Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma","enrollment":8},{"nctId":"NCT07183852","phase":"PHASE1","title":"Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2026-03","conditions":"Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma","enrollment":18},{"nctId":"NCT03108495","phase":"PHASE2","title":"Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma","status":"TERMINATED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2017-06-22","conditions":"Cervical Carcinoma","enrollment":210},{"nctId":"NCT07106814","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-08-29","conditions":"Advanced Solid Tumors","enrollment":36},{"nctId":"NCT05640193","phase":"PHASE1","title":"A Study of LN-144 in People With Metastatic Melanoma to the Brain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-11-25","conditions":"Metastatic Melanoma","enrollment":10},{"nctId":"NCT06204991","phase":"PHASE1","title":"To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma","status":"RECRUITING","sponsor":"Inge Marie Svane","startDate":"2025-04-01","conditions":"Melanoma Stage III, Melanoma Stage IV, Melanoma","enrollment":10},{"nctId":"NCT06084299","phase":"PHASE1","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer","status":"RECRUITING","sponsor":"Zhiyong Huang","startDate":"2020-05-27","conditions":"Liver Cancer","enrollment":16},{"nctId":"NCT02652455","phase":"EARLY_PHASE1","title":"Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-03-08","conditions":"Melanoma (Skin), Skin Cancer","enrollment":11},{"nctId":"NCT07105176","phase":"PHASE1","title":"HS-IT101 Injection for Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","startDate":"2025-08-30","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":12},{"nctId":"NCT04217473","phase":"PHASE1","title":"TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma","status":"COMPLETED","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2020-02-26","conditions":"Metastatic Melanoma","enrollment":17},{"nctId":"NCT06047977","phase":"PHASE1","title":"Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-06-02","conditions":"Lymphocytes","enrollment":30},{"nctId":"NCT05727904","phase":"PHASE3","title":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2023-03-30","conditions":"Metastatic Melanoma, Unresectable Melanoma, Melanoma","enrollment":670},{"nctId":"NCT03991741","phase":"PHASE1","title":"Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors","status":"TERMINATED","sponsor":"Gregory Daniels","startDate":"2020-10-07","conditions":"Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer","enrollment":3},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT05398640","phase":"","title":"Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release","status":"AVAILABLE","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"","conditions":"Unresectable Melanoma, Metastatic Melanoma","enrollment":""},{"nctId":"NCT06190249","phase":"PHASE1","title":"Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma","status":"WITHDRAWN","sponsor":"James Isaacs, MD","startDate":"2024-12-02","conditions":"Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IIID Melanoma","enrollment":""},{"nctId":"NCT03610490","phase":"PHASE2","title":"Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-16","conditions":"Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma, Metastatic Ovarian Carcinoma","enrollment":16},{"nctId":"NCT05576077","phase":"PHASE1","title":"A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Turnstone Biologics, Corp.","startDate":"2023-01-17","conditions":"Breast Cancer, Colorectal Cancer, Uveal Melanoma","enrollment":31},{"nctId":"NCT02278887","phase":"PHASE3","title":"Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2014-09-23","conditions":"Metastatic Melanoma","enrollment":168},{"nctId":"NCT04643574","phase":"PHASE1","title":"NeoTIL in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2021-03-09","conditions":"Solid Tumor, Adult","enrollment":42},{"nctId":"NCT03475134","phase":"PHASE1","title":"TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2018-02-21","conditions":"Metastatic Melanoma","enrollment":18},{"nctId":"NCT06630611","phase":"PHASE2","title":"Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)","status":"RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2025-01-15","conditions":"Melanoma, Non Small Cell Lung Cancer, Cervical Cancer","enrollment":40},{"nctId":"NCT06783270","phase":"PHASE1","title":"T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma","status":"RECRUITING","sponsor":"Inge Marie Svane","startDate":"2024-12-16","conditions":"Melanoma Metastatic","enrollment":10},{"nctId":"NCT02500576","phase":"PHASE2","title":"Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-07","conditions":"Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7","enrollment":18},{"nctId":"NCT05361174","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2022-07-20","conditions":"Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer","enrollment":53},{"nctId":"NCT02926053","phase":"PHASE1","title":"TIL Therapy for Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2016-12","conditions":"Metastatic Renal Cell Carcinoma","enrollment":5},{"nctId":"NCT04111510","phase":"PHASE2","title":"Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-12-23","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":6},{"nctId":"NCT06532812","phase":"PHASE1, PHASE2","title":"TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2024-08-22","conditions":"Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic","enrollment":85},{"nctId":"NCT06532799","phase":"PHASE1, PHASE2","title":"TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2024-09-10","conditions":"Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma","enrollment":75},{"nctId":"NCT05141474","phase":"EARLY_PHASE1","title":"Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors","status":"RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2021-10-28","conditions":"Epithelial Tumors, Malignant, Malignant Solid Tumor","enrollment":10},{"nctId":"NCT06530303","phase":"PHASE1, PHASE2","title":"Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2024-09-29","conditions":"Colorectal Cancer, Colon Cancer, Rectum Cancer","enrollment":85},{"nctId":"NCT06640582","phase":"PHASE1, PHASE2","title":"TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2024-10-20","conditions":"Brain Tumor, Brain Metastases, Brain Cancer","enrollment":85},{"nctId":"NCT06538012","phase":"PHASE1, PHASE2","title":"TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2024-08-20","conditions":"Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell","enrollment":85},{"nctId":"NCT01740557","phase":"PHASE1, PHASE2","title":"Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-28","conditions":"Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7","enrollment":10},{"nctId":"NCT00863330","phase":"PHASE2","title":"Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2009-02","conditions":"Melanoma (Skin)","enrollment":14},{"nctId":"NCT05831033","phase":"EARLY_PHASE1","title":"Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-23","conditions":"Solid Tumor","enrollment":16},{"nctId":"NCT01883297","phase":"PHASE1","title":"\"Re-Stimulated\" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2015-01","conditions":"Recurrent, Platinum-resistant, High Grade Serous Ovarian Cancer","enrollment":3},{"nctId":"NCT03658785","phase":"PHASE1, PHASE2","title":"Immunotherapy for the Treatment of Advanced Solid Tumor","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2020-04-28","conditions":"Recurrence Tumor, Metastatic Cancer, Solid Tumor","enrollment":40},{"nctId":"NCT05050006","phase":"PHASE2","title":"ITIL-168 in Advanced Melanoma","status":"TERMINATED","sponsor":"Instil Bio","startDate":"2021-10-07","conditions":"Advanced Cutaneous Melanoma","enrollment":29},{"nctId":"NCT04165967","phase":"PHASE1","title":"Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-09-17","conditions":"Advanced Melanoma","enrollment":9},{"nctId":"NCT06151847","phase":"PHASE2","title":"Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma","status":"UNKNOWN","sponsor":"University of Kansas Medical Center","startDate":"2023-12-21","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":12},{"nctId":"NCT05451784","phase":"PHASE1, PHASE2","title":"Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS","status":"RECRUITING","sponsor":"Fundacio Clinic Barcelona","startDate":"2022-07-20","conditions":"Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT06107894","phase":"PHASE1","title":"TIL Therapy for Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"NeogenTC","startDate":"2024-01","conditions":"Advanced Breast Cancer, Advanced Lung Cancer","enrollment":12},{"nctId":"NCT03083873","phase":"PHASE2","title":"Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck","status":"COMPLETED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2017-01-09","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":64},{"nctId":"NCT03215810","phase":"PHASE1","title":"Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-10-11","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT05903937","phase":"PHASE1","title":"Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2023-12-31","conditions":"Uveal Melanoma, Metastatic Cutaneous Melanoma","enrollment":6},{"nctId":"NCT01995344","phase":"PHASE2","title":"TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment","status":"TERMINATED","sponsor":"The Christie NHS Foundation Trust","startDate":"2014-03-01","conditions":"Metastatic Melanoma","enrollment":2},{"nctId":"NCT03287674","phase":"PHASE1, PHASE2","title":"TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2017-10-09","conditions":"Metastatic Ovarian Cancer","enrollment":7},{"nctId":"NCT03166397","phase":"PHASE2","title":"Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients","status":"RECRUITING","sponsor":"Sheba Medical Center","startDate":"2017-06-05","conditions":"Malignant Melanoma Stage IV","enrollment":30},{"nctId":"NCT01993719","phase":"PHASE2","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-12-12","conditions":"Metastatic Melanoma","enrollment":33},{"nctId":"NCT02414945","phase":"PHASE1, PHASE2","title":"TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2015-05-15","conditions":"Pleural Mesothelioma","enrollment":9},{"nctId":"NCT05393635","phase":"PHASE1","title":"ITIL-168 in Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"Instil Bio","startDate":"2022-08","conditions":"Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT05649618","phase":"EARLY_PHASE1","title":"TIL Cells for the Treatment of the Advanced Solid Tumors Patients","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2022-12-05","conditions":"Solid Tumor","enrollment":42},{"nctId":"NCT01807182","phase":"PHASE2","title":"Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-08-20","conditions":"Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7","enrollment":11},{"nctId":"NCT01946373","phase":"PHASE1","title":"T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2013-10","conditions":"Melanoma","enrollment":20},{"nctId":"NCT05539768","phase":"EARLY_PHASE1","title":"Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-10-08","conditions":"Advanced Solid Tumor","enrollment":8},{"nctId":"NCT05505812","phase":"EARLY_PHASE1","title":"Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-10-08","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT05366478","phase":"PHASE1","title":"A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","startDate":"2022-05-30","conditions":"Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma","enrollment":15},{"nctId":"NCT05475847","phase":"PHASE1","title":"Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-07","conditions":"Cervical Cancer","enrollment":20},{"nctId":"NCT03526185","phase":"EARLY_PHASE1","title":"A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes","status":"TERMINATED","sponsor":"Yale University","startDate":"2018-02-06","conditions":"Metastatic Melanoma","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TIL + IL2","genericName":"TIL + IL2","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TIL + IL-2 combines tumor-infiltrating lymphocytes with interleukin-2 to expand and activate patient-derived T cells for adoptive cell therapy against cancer. Used for Metastatic melanoma, Advanced solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}